https://adisinsight.springer.com/trials/700059410?error=cookies_not_supported&code=25004545-0daf-4d7a-a22c-b2971e8da3df
The Effect of Hepatic Impairment on the Pharmacokinetics of Aleglitazar: A Multiple-centre,...
This open-label study assessed the effects of hepatic impairment on the pharm acokinetics of a single oral dose of aleglitazar in subjects with mild or modera
the effecthepaticimpairment